📊 INMB Key Takeaways
Is INMB a Good Investment? Thesis Analysis
Inmune Bio is a pre-revenue/early-stage biotech company with severely negative profitability and cash burn, burning approximately $20.5M in free cash flow annually against minimal revenue of $50K. Despite adequate short-term liquidity (4.17x current ratio and $27.7M cash), the company faces existential runway concerns at current burn rates, with only 16-18 months of cash remaining if burn continues unabated.
Why Buy INMB? Key Strengths
- Strong current ratio of 4.17x indicates short-term liquidity to fund operations
- Positive stockholders equity of $25.4M provides modest balance sheet cushion
- Cash position of $27.7M adequate for near-term R&D and clinical trial funding
INMB Investment Risks to Consider
- Massive operating losses of -$41.9M with operating margin of -83,818% indicating unsustainable business model
- Severe cash burn of -$20.5M annually with only ~16 months of runway at current burn rates
- Revenue collapse of -91% YoY coupled with zero revenue growth trajectory and no clear path to profitability
- Long-term debt of $15M represents 59% of equity and compounds financing burden
- No insider buying activity in 90 days suggests lack of management confidence
- Negative interest coverage of -69.0x means operating cash flow cannot service debt obligations
Key Metrics to Watch
- Monthly cash burn rate and runway extension announcements
- Clinical trial progress and pipeline advancement milestones
- Revenue trajectory and any commercial partnerships or licensing deals
- Cash position depletion timeline and potential financing needs
- Operating expense reduction and burn optimization initiatives
INMB Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 4.17x current ratio provides a solid financial cushion.
INMB Profitability Ratios
INMB vs Healthcare Sector
How Inmune Bio, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is INMB Overvalued or Undervalued?
Based on fundamental analysis, Inmune Bio, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
INMB Balance Sheet & Liquidity
INMB 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Inmune Bio, Inc.'s revenue has grown significantly by 1,320% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.67 indicates the company is currently unprofitable.
INMB Growth Metrics (YoY)
INMB Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $14.0K | -$6.5M | $-0.24 |
| Q2 2025 | $14.0K | -$9.7M | $-0.50 |
| Q1 2025 | $14.0K | -$9.7M | $-0.43 |
| Q3 2024 | $14.0K | -$6.5M | $-0.48 |
| Q2 2024 | $14.0K | -$6.5M | $-0.36 |
| Q1 2024 | $14.0K | -$6.5M | $-0.36 |
| Q3 2023 | $43.0K | -$6.5M | $-0.43 |
| Q2 2023 | $16.0K | -$6.5M | $-0.36 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
INMB Capital Allocation
INMB SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Inmune Bio, Inc. (CIK: 0001711754)
📋 Recent SEC Filings
❓ Frequently Asked Questions about INMB
What is the AI rating for INMB?
Inmune Bio, Inc. (INMB) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are INMB's key strengths?
Claude: Strong current ratio of 4.17x indicates short-term liquidity to fund operations. Positive stockholders equity of $25.4M provides modest balance sheet cushion.
What are the risks of investing in INMB?
Claude: Massive operating losses of -$41.9M with operating margin of -83,818% indicating unsustainable business model. Severe cash burn of -$20.5M annually with only ~16 months of runway at current burn rates.
What is INMB's revenue and growth?
Inmune Bio, Inc. reported revenue of $50.0K.
Does INMB pay dividends?
Inmune Bio, Inc. does not currently pay dividends.
Where can I find INMB SEC filings?
Official SEC filings for Inmune Bio, Inc. (CIK: 0001711754) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is INMB's EPS?
Inmune Bio, Inc. has a diluted EPS of $-1.68.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is INMB a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Inmune Bio, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is INMB stock overvalued or undervalued?
Valuation metrics for INMB: ROE of -160.3% (sector avg: 15%), net margin of -81,338.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy INMB stock in 2026?
Our dual AI analysis gives Inmune Bio, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is INMB's free cash flow?
Inmune Bio, Inc.'s operating cash flow is $-19.6M, with capital expenditures of $899.0K. FCF margin is -41,074.0%.
How does INMB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -81,338.0% (avg: 12%), ROE -160.3% (avg: 15%), current ratio 4.17 (avg: 2).